VIDEO: Combo therapy improves outcomes for Black patients with metastatic prostate cancer
Click Here to Manage Email Alerts
CHICAGO — In this Healio video exclusive, Andrew Armstrong, MD, discusses the results of the use of abiraterone acetate and apalutamide plus prednisone in Black and White patients with metastatic castrate-resistant prostate cancer.
The phase 2 PANTHER study presented by Armstrong and Dan George, MD, which were presented at the ASCO Annual Meeting, showed that treatment with the combination of abiraterone acetate and apalutamide plus prednisone (AAAP) resulted in clinical efficacy – better OS, improved RPFS and improved PSA outcomes – in Black patients with metastatic castrate-resistant prostate cancer when compared to their matched white cohort.
“Black men may actually derive benefits from dual AR blockade, both against the receptor and against androgen synthesis,” Armstrong, medical oncologist at Duke Cancer Institute Center for prostate and urologic cancers, said.
Black patients were underrepresented in the phase 3 ACIS trial, which was negative for improving survival with this combination. Further studies of AAAP combination therapy among Black patients with advanced prostate cancer are needed, according to researchers.
“This speaks to the importance of diversity and inclusion in our clinical trials so that we may learn which patients benefit the most from these targeted therapies,” Armstrong said.
References:
- George D, et al. Abstract 5015. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Healio interviews
Read more about
Click Here to Manage Email Alerts